BLUE: יחס מחיר להכנסות bluebird bio Inc.

bluebird bio, Inc. (BLUE) leads in blood gene therapy, ensuring high margins and stable cash flow. The price-to-sales ratio demonstrates valuation dynamics, where 0.50 reflects the latest metric value. Growth depends on Lyfgenia sales and insurance coverage, while the strategy shifts toward the industrial scaling of approved vectors and the implementation of commercial protocols.

To select assets with a high margin of safety, analyzing the price-to-sales ratio is critical, as it allows for an assessment of business overvaluation relative to generated cash flow. This price-to-sales multiple reflects the monetization efficiency of bluebird bio, Inc. (BLUE) gene therapies, helping investors correlate the company's valuation with revenues from rare disease treatments and partnership payments.